Matthew F. Buas, MS, PhD

Associate Attending Epidemiologist

Share
Share

Education

MS, University of Washington (2013); PhD, University of Pennsylvania (2009)

Dr. Buas’ primary research focus is the molecular/genetic epidemiology of esophageal adenocarcinoma (EAC) and its precursor lesion, Barrett’s esophagus (BE). As such, Dr. Buas designs and leads studies investigating the role of inherited genetics in the etiology of BE/EAC using a combination of statistical, computational, and experimental approaches. These include targeted and genome-wide discovery scans to identify novel genetic susceptibility loci; multi-omics informatics pipelines to prioritize single nucleotide variants based on estimated regulatory potential; and laboratory-based functional assays to validate and characterize candidate functional/causal variants, gene targets, and disease pathways. A second area of interest is the identification of novel molecular signatures and biomarkers of esophageal and ovarian cancers using high-throughput omics profiling technologies.The long-term translational goal of Dr. Buas’ research is to advance new strategies for cancer prevention, risk assessment, and early detection. His work is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI).

Publications

  1. Ali MW, Chen J, Yan L, Wang X, Dai JY, Vaughan TL, Casey G*, Buas MF*. A risk variant for Barrett’s esophagus and esophageal adenocarcinoma at chr8p23.1 affects enhancer activity and implicates multiple gene targets. Hum Mol Genet. 2022 Jun 29;. doi: 10.1093/hmg/ddac141. [Epub ahead of print] PMID: 35766871. *Co-corresponding
  2. Chen J, Ali MW, Yan L, Dighe SG, Dai JY, Vaughan TL, Casey G*, Buas MF*. Prioritization and functional analysis of GWAS risk loci for Barrett’s esophagus and esophageal adenocarcinoma. Hum Mol Genet. 2022 Feb 3;31(3):410-422. doi: 10.1093/hmg/ddab259. PMID: 34505128; PMCID: PMC8825357. *Co-corresponding
  3. Buas MF, Drescher CW, Urban N, Li CI, Bettcher L, Hait NC, Moysich KB, Odunsi K, Raftery D, Yan L. Quantitative global lipidomics analysis of patients with ovarian cancer versus benign adnexal mass. Sci Rep. 2021 Sep 13;11(1):18156. doi: 10.1038/s41598-021-97433-x. PMID: 34518593; PMCID: PMC8438087.
  4. Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, Gharahkhani P, Palles C, Lagergren J, Fitzgerald RC, Ye W, Caldas C, Bird NC, Shaheen NJ, Bernstein L, Gammon MD, Wu AH, Hardie LJ, Pharoah PD, Liu G, Iyer P, Corley DA, Risch HA, Chow WH, Prenen H, Chegwidden L, Love S, Attwood S, Moayyedi P, MacDonald D, Harrison R, Watson P, Barr H, deCaestecker J, Tomlinson I, Jankowski J, Whiteman DC, MacGregor S, Vaughan TL, Madeleine MM. Germline variation in inflammation-related pathways and risk of Barrett’s oesophagus and oesophageal adenocarcinoma. Gut. 2017 Oct;66(10):1739-1747. doi: 10.1136/gutjnl-2016-311622. PMID: 27486097; PMCID: PMC5296402.
  5. Gharahkhani P*, Fitzgerald RC*, Vaughan TL*, Palles C*, Gockel I*, Tomlinson I*, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RGP, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J. Genome-wide association studies in oesophageal adenocarcinoma and Barrett’s oesophagus: a large-scale meta-analysis. Lancet Oncol. 2016 Oct;17(10):1363-1373. doi: 10.1016/S1470-2045(16)30240-6. PMID: 27527254; PMCID: PMC5052458. *Contributed equally

View a full listing of Matthew F. Buas’ journal articles.